Objectives: 1. Perform Bulk RNA-seq transcriptome sequencing on enrolled samples to screen sepsis-specific mRNA diagnostic biomarkers and evaluate their diagnostic efficacy for early sepsis in the ICU; establish a molecular risk stratification system for sepsis based on mRNA expression profiles, and clarify the immunobiological characteristics, clinical manifestation differences, and prognostic risk levels of each stratification. 2. Integrate core indicators screened from transcriptome sequencing, open-source databases, and previous studies to establish and optimize an RT-LAMP rapid detection method for core sepsis targets, validate its diagnostic accuracy, specificity, and reproducibility, and construct a rapid sepsis diagnostic model adapted to bedside scenarios. 3. Integrate core indicators screened from open-source databases and previous studies to screen sepsis-specific diagnostic biomarkers in plasma and urine via PRM and metabolomics, complete protein/metabolic level validation using immunological methods (ELISA), construct a combined diagnostic model for sepsis, and complete internal validation and efficacy evaluation.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Whole-genome mRNA expression profiles of the sepsis group and the non-sepsis group, the list of core diagnostic biomarkers screened by multi-algorithm cross-validation (WGCNA + LASSO + SVM-RFE), and their diagnostic efficacy for early sepsis in the ICU.
Timeframe: Within 24 hours of ICU admission (baseline)
Results of sepsis molecular risk stratification, and differences in clinical characteristics, biological characteristics, and prognosis among different stratifications
Timeframe: At baseline (within 24 hours of ICU admission)
Methodological performance evaluation of the RT-LAMP rapid diagnostic method and its early diagnostic efficacy for sepsis, reporting AUC, sensitivity, specificity, positive/negative predictive values.
Timeframe: At baseline (within 24 hours of ICU admission)
Early diagnostic efficacy of protein/metabolic biomarkers in plasma/urine for sepsis, and AUC, sensitivity, specificity, positive/negative predictive values of the combined diagnostic model.
Timeframe: At baseline (within 24 hours of ICU admission